Biodexa Pharmaceuticals (BDRX) Return on Invested Capital (2020 - 2024)

Biodexa Pharmaceuticals (BDRX) has 4 years of Return on Invested Capital data on file, last reported at 0.25% in Q4 2024.

• For the quarter ending Q4 2024, Return on Invested Capital changed N/A year-over-year to 0.25%; the trailing twelve-month figure through Dec 2024 stood at 0.25% (changed N/A YoY), and the FY2025 full-year result was 0.04%, up 21.0% from the prior year.
• Return on Invested Capital retreated to 0.25% in Q4 2024, from 0.09% in the prior quarter.
• In the past five years, Return on Invested Capital ranged from a high of 0.08% in Q3 2020 to a low of 0.31% in Q3 2021.
• A 4-year average of 0.18% and a median of 0.2% in 2021 frame the typical range for Return on Invested Capital.
• Across the five-year window, Return on Invested Capital dropped 23 bps in 2021 and rose 11 bps in 2022, its largest moves.
• Tracing BDRX's Return on Invested Capital over 4 years: stood at 0.09% in 2020, then plunged by 118 bps to 0.2% in 2021, then soared by 56 bps to 0.09% in 2022, then tumbled by 192 bps to 0.25% in 2024.
• Business Quant data shows BDRX's Return on Invested Capital at 0.25% in Q4 2024, 0.09% in Q4 2022, and 0.26% in Q3 2022.